Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 2Phase 3 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 103Lymphoma, Large B-Cell, Diffuse 32Neoplasms 23Lymphoma, Non-Hodgkin 20Lymphoma, Follicular 20Lymphoma 19Multiple Myeloma 15Lymphoma, B-Cell 11Neoplasm Metastasis 10Recurrence 8Lymphoma, T-Cell, Peripheral 7Prostatic Neoplasms, Castration-Resistant 5Prostate Cancer Metastatic 5Metastatic Castration-resistant Prostate Cancer 5Lymphoma, Mantle-Cell 5Hematologic Diseases 5Lymphoma, B-Cell, Marginal Zone 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Metastatic Castration-Resistant Prostate Cancer 3Leukemia, Lymphocytic, Chronic, B-Cell 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Pain 2Metastatic Castration Resistant Prostate Cancer 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphatic Diseases 2Leukemia 2Graft vs Host Disease 2

Interventions

enzalutamide 5Prednisone 5cabazitaxel 4Docetaxel 3Abiraterone Acetate 3fludrocortisone acetate 1Zuclomiphene 1XRP6258 1Standard of Care 1Prednisolone 1Midazolam 1LY3023414 1Injections 1Hydrocortisone 1Dexamethasone 1Abituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Prostate Cancer Metastatic × Prednisone × Clear all
NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,310 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT02485691 2022-05-27

CARD

Sanofi

Phase 4 Completed
255 enrolled 21 charts
Genitourinary

Prostate Cancer Metastatic

NCT02379390 2019-06-21

PRIMCAB

Sanofi

Phase 2 Terminated
8 enrolled 8 charts
Genitourinary

Prostate Cancer Metastatic

NCT01718353 2017-11-20

TAXYNERGY

Sanofi

Phase 2 Completed
63 enrolled 13 charts
Genitourinary

Prostate Cancer Metastatic

NCT02074137 2016-06-02

Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer

Sanofi

Phase 4 Completed
10 enrolled
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡